CAMBRIDGE, England,
March 25, 2022 /PRNewswire/
-- Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it
has received six recognitions from CiteAb at their annual industry
awards, the highest of any participant evaluated this year. This
record number of acknowledgments follows a year of substantial
investment for Abcam to enable life sciences researchers from
academia and industry to advance discoveries and deliver faster
breakthroughs.
First and foremost, Abcam was recognized for its initiatives to
improve standards in the reagent industry. Its "Recombinant
Multiclonal" range, which combines the benefits of recombinant
monoclonal and polyclonal antibodies, was awarded "Innovation of
the Year" by a panel of experts while Abcam was highly
commended in the "Recombinant Antibody Supplier of the Year"
category. The Company also won the "Supplier Succeeding in KO
Validation" award for its antibody validation program. All
three awards demonstrate Abcam's commitment to continually
improving scientific reproducibility in life sciences, which
benefits the research community and society globally.
Prof. Giovanna Roncador, Head of the Monoclonal Antibodies
Unit/Biotechnology Program at the Spanish National Cancer Research
Center (CNIO), Founder and Chair of EuroMabNet and recipient of the
2022 CiteAb award for "Significant Individual Impact" said:
"As a cancer researcher and antibody engineer, I firmly believe
that advancing science goes hand in hand with improving standards
for reagent quality. I am delighted but not surprised to see
Abcam's success in the CiteAb Awards, as, this year again, they
have taken a number of strides forward to deliver the scientific
community the tools they need for success."
Dr. Alejandra Solache, SVP
Research and Development at Abcam and recipient of the 2021 CiteAb
award for "Significant Individual Impact" commented: "We are
excited to see our dedication to delivering higher standards being
acknowledged as we continually look for new ways in which we can
break barriers and set new industry standards for improving
reproducibility in science. Thank you to CiteAb, the judging panels
and the researchers with whom we share the same passion to drive
life sciences forward."
Finally, this year's CiteAb awards also recognize Abcam's effort
to address the growing demand of the sector for high-performance,
reproducible, off-the-shelf assays with the acquisition of
BioVision for $340M. Offering a
platform for greater innovation and increasing access to
biochemical assays and cellular assays, the deal is
recognized for its potential to lay the foundations for future
positive impact across the life sciences sector.
Abcam's 2022 full list of recognitions include:
Acquisition of the Year – Winner (BioVision)
Innovation of the Year – Winner (Recombinant Multiclonal range)
Supplier Succeeding in KO validation – Winner
Recombinant Antibody Supplier of the Year - Highly Commended
Supplier Succeeding in Cancer Research - Highly Commended
Supplier Succeeding in Sars-Cov-2 research - Highly Commended
About Abcam plc
As a global life sciences company, Abcam identifies, develops,
and distributes high-quality biological reagents and tools that are
crucial to research, drug discovery and diagnostics. Working across
the industry, the Company supports life scientists to achieve their
mission, faster.
Abcam partners with life sciences organizations to co-create
novel binders for use in drug discovery, in vitro
diagnostics and therapeutics, driven by the Company's proprietary
discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is
helping advance the global understanding of biology and causes of
disease, which enables new treatments and improved health. The
Company's pioneering data-sharing approach gives scientists
increased confidence in their results by providing validation, user
comments and peer-reviewed citations for its 90,000 products.
With a direct presence in America, Asia and Europe, many of Abcam's over 1,700-strong team
are located in the world's leading life sciences research hubs,
complementing a global network of service and support.
To find out more, please
visit www.abcam.com and corporate.abcam.com
Logo -
https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg